Use of Nafamostat Mesilate as an Anticoagulant during Extracorporeal Membrane Oxygenation by Han, Sang Jin et al.
© 2011 The Korean Academy of Medical Sciences.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
pISSN 1011-8934
eISSN 1598-6357
Use of Nafamostat Mesilate as an Anticoagulant during 
Extracorporeal Membrane Oxygenation
Although the incidence of bleeding complications during extracorporeal membrane 
oxygenator (ECMO) support has decreased in various trials, bleeding is still the most fatal 
complication. We investigated the ideal dosage and efficacy of nafamostat mesilate for 
use with ECMO in patients with acute cardiac or respiratory failure. We assessed 73 
consecutive patients who received ECMO due to acute cardiac or respiratory failure 
between January 2006 and December 2009. To evaluate the efficacy of nafamostat 
mesilate, we divided the patients into 2 groups according to the anticoagulants used 
during ECMO support. All patients of nafamostat mesilate group were male with a mean 
age of 49.2 yr. Six, 3, 5, and 3 patients were diagnosed with acute myocardial infarction, 
cardiac arrest, septic shock, and acute respiratory distress syndrome, respectively. The 
mean dosage of nafamostat mesilate was 0.64 mg/kg/hr, and the mean duration of ECMO 
was 270.7 hr. The daily volume of transfused packed red blood cells, fresh frozen plasma, 
and cryoprecipitate and the number of complications related to hemorrhage and thrombosis 
was lower in the nafamostat mesilate group than in the heparin group. Nafamostat 
mesilate should be considered as an alternative anticoagulant to heparin to reduce bleeding 
complications during ECMO.
Key Words: Extracorporeal Membrane Oxygenation; Anticoagulants; Heparin; Nafamostat; 
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INTRODUCTION
When the treatment of acute heart failure and respiratory failure 
is difficult with existing conventional methods, treatment with 
an extracorporeal membrane oxygenator (ECMO) has become 
an alternative (1). Although heparin has been used as an anti-
coagulant among a variety of methods to reduce bleeding com-
plications during ECMO usage, bleeding complications still oc-
cur in 10%-30% of patients (1-4). 
  Nafamostat mesilate, a synthetic protease inhibitor with a short 
half life, has been widely used as an anticoagulant for hemodial-
ysis patients with a tendency to bleed (5-7). It has been reported 
that nafamostat mesilate produces good results when it is ap-
plied for anticoagulation to cardiac surgery and ECMO; howev-
er, different dosages were used in each study (8-12). 
  The present study investigated the ideal dosage and efficacy 
of nafamostat mesilate for use with ECMO in patients with acute 
cardiac or respiratory failure.
MATERIALS AND METHODS
We retrospectively reviewed the records of 73 consecutive pa-
tients who received ECMO due to acute cardiac or respiratory 
failure between January 2006 and December 2009. Nafamostat 
mesilate (SK Chemicals Life Science Biz., Seoul, Korea; licensed 
by Torii Pharmaceutical Co., Ltd., Tokyo, Japan) was used as an 
anticoagulant in 17 patients and 56 patients received heparin. 
We excluded 5 of the 56 heparin patients because they under-
went an operation just after ECMO: 3 pulmonary artery throm-
boembolectomies due to acute pulmonary thromboembolism, 
1 coronary artery bypass graft due to acute myocardial infarction, 
and 1 reoperation due to cardiac arrest at 10 hr after receiving a 
coronary artery bypass graft. We started to use nafamostat me-
silate in October 2008 as an anticoagulant during ECMO support 
in patients with acute renal failure or with a high risk of bleed-
ing due to antiplatelet medication. 
  The criteria for venoarterial ECMO use was refractory cardio-
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to conventional therapy. The inclusion criteria were a systolic 
blood pressure < 80 mmHg despite adequate intravascular vol-
ume replacement and the infusion of high dose catecholamines 
(dopamine > 30 µg/kg/min and/or norepinephrine > 0.2 µg/kg/ 
min). The inclusion criteria for venovenous ECMO were based 
on the lung dysfunction measured with a PaO2/FiO2 ratio < 100 
for an FiO2 of 1.0, or an arterial blood gas pH < 7.25 due to hyper-
capnia despite receiving the optimal treatment. 
  Three types of centrifugal pumps were used for the ECMO sys-
tem: Capiox Emergency Bypass System
® (Terumo, Inc., Tokyo, 
Japan), Bio-pump
® (Medtronic Inc, Minneapolis, MN, USA), and 
Centrifugal Rotaflow pump
® (Maquet Inc., Hirrlingen, Germa-
ny). We used 3 types of polypropylene hollow-fiber membrane 
oxygenators: CAPIOX
® RX25 (Termo, Inc.), D903 AVANT (Sorin 
Group Italia S.R.L., Mirandola Modena, Italy), and Capiox Emer-
gency Bypass System
® (Terumo, Inc.). To enable ECMO, all pa-
tients received 17-21 Fr arterial cannulae (DLP
®: Medtronic Inc., 
or RMI
®: Edward’s Lifescience LLC, Irvine, CA, USA) and 17-28 
Fr venous cannulae (DLP
®: Medtronic Inc. or RMI
®: Edward’s 
Lifescience LLC) according to the patient’s size. ECMO was ad-
ministered in the cardiac catheterization laboratory, except for 
3 patients. After the intravenous injection of 10 mg/kg heparin, 
the femoral artery and femoral vein were cannulated percuta-
neously using the Seldinger method, except for 1 patient who 
was cannulated after an inguinal incision. In the case of veno-
venous ECMO, both femoral veins were cannulated.
  Initially, 3 patients were observed for a high infusion rate of 
nafamostat mesilate (1.15-2.19 mg/kg/hr) to maintain the acti-
vated clotting time (ACT) at 140-180 sec. From the 4th patient, 
nafamostat mesilate was adjusted at 0.41-0.93 mg/kg/hr accord-
ing to the activated partial thromboplastin time (aPTT; target 
range: 60-80 sec). The heparin patients received a continuous 
infusion at a rate of 1-2 mg/kg/hr to maintain the ACT at 140-
180 sec. The patients with acute myocardial infarction (AMI) who 
received percutaneous coronary intervention were administered 
aspirin (250 mg) and clopidogrel (300 mg) on the day of the pro-
cedure, and received aspirin (200 mg) and clopidogrel (75 mg) 
on the following day. 
  We tried to maintain the hematocrit levels > 35% and the plate-
let count > 80,000 per µL. If the hematocrit and platelet counts 
fell below these levels, we transfused blood products. In addi-
tion, fresh frozen plasma (FFP) and cryoprecipitate transfusion 
was performed once after 3 or 4 days according to the occurrence 
of hemorrhagic complications.
  After weaning was successfully performed, the cannulae were 
surgically removed in the operating room to avoid complica-
tions such as leg ischemia, aneurysm, or arteriovenous fistula. 
Nafamostat mesilate was discontinued after removing the can-
nulae, while heparin was discontinued at 12 hr before the can-
nulae were removed. 
  The DBSTAT program (ver. 4.1; DBSTAT Co., Chuncheon, 
Korea) was used for all statistical analysis. Categorical variables 
were expressed as percentages and evaluated with Pearson’s 
chi-square test or Fisher’s exact test. Continuous variables were 
expressed as the mean and standard deviation and were evalu-
ated with Student’s t test or the Mann Whitney U-test. All P val-
ues were 2 sided, and P < 0.05 was considered significant.
Ethics statement
This study received institutional review board approval of the 
Hallym University Chuncheon Sacred Heart Hospital (IRB No. 
2010-60). Informed consent was exempted by the board because 
of the retrospective study.
RESULTS
The clinical characteristics of the 17 patients treated with nafa-
mostat mesilate during ECMO support are as follows. All pa-
tients were male, and their mean age was 49.2 yr. Six, 3, 5, and 3 
patients were diagnosed with AMI, cardiac arrest, septic shock, 
and acute respiratory distress syndrome (ARDS), respectively. 
ECMO in the venoarterial mode was applied to 14 patients. The 
mean dosage of nafamostat mesilate was 0.64 mg/kg/hr to main-
tain an aPTT of 60-80 sec. The mean duration of ECMO was 270.7 
hr. Seven patients survived and were discharged. 
  To evaluate the efficacy of nafamostat mesilate, the patients 
were divided into 2 groups according to the anticoagulants used 
during ECMO. A clinical comparison between the nafamostat 
mesilate and heparin groups is shown in Table 1. The patients’ 
ages, sex, diagnosis, ECMO duration, and peak blood urea ni-
trogen, and total and direct bilirubin levels were found to be 
statistically significant variables (P < 0.05). The number of mor-
talities within 24 hr after applying ECMO in the heparin group 
was 14, which was 1 in the nafamostat mesilate group; however, 
this was not a significant difference (P = 0.092). 
  The differences between hemorrhagic and thrombotic com-
plications are shown in Table 2. The average time of oxygenator 
use in the nafamostat mesilate group was longer than in the hep-
arin group (P = 0.003). The daily transfusion volume of packed 
RBCs, FFP, and cryoprecipitate was lower in the nafamostat me-
silate group than in the heparin group (P < 0.001, P < 0.001, P = 
0.035). The number of complications related to hemorrhage and 
thrombosis was higher in the heparin group (34 in 31 patients) 
than in the nafamostat mesilate group (4 complications in 4 pa-
tients) (P = 0.011). The long term survival and cause of death 
according to anticoagulants is shown in Table 3. The ECMO sup-
port of 8 patients in the heparin group was withdrawn because 
of uncontrolled bleeding. The nafamostat mesilate group pro-
vided a better survival rate than the heparin group (P = 0.048). 
Sixteen survivors were discharged from the hospital and found 
still alive in December 2010. Han SJ, et al.  •  Use of Nafamostat Mesilate during ECMO
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DISCUSSION
The number of cases in which ECMO is used to treat cardiopul-
monary failure is increasing. Although the incidence of bleed-
ing complications has decreased in various trials, bleeding re-
mains one of the most fatal complications. Nafamostat mesilate 
is a synthetic serine protease inhibitor with a very short half-life 
that inhibits coagulation, fibrinolysis, and platelet aggregation 
by inactivating the action of thrombin, activated coagulation 
factors XIIa and Xa, complement C1r and C1s, plasmin, trypsin, 
and kallikrein (13-15). Nafamostat mesilate has been used as 
Table 1. Patients’ clinical characteristics according to anticoagulants
Characteristics Nafamostat mesilate (n = 17) Heparin (n = 51) P value
Dermographics
   Age (yr, mean ± SD)
   Gender (male/female)
   BMI (kg/m
2, mean ± SD)
 
   49.2 ± 17.4
17/0
 24.8 ± 4.8
 
  61.7 ± 15.1
32/19
24.4 ± 3.6
 
0.006
0.002
0.754
Diagnosis, No. (%)
   AMI
   Cardiac arrest
   Cardiogenic shock
   Septic shock
   ARDS
 
6 (35)
   3 (17.6)
0
   5 (29.4)
   3 (17.6)
 
37 (72.5)
2 (3.9)
3 (5.9)
2 (3.9)
  7 (13.7)
0.004
Cardiac arrest before ECMO, No. (%)    9 (52.9) 38 (74.5) 0.096
ECMO during CPR, No. (%)    8 (47.1) 33 (64.7) 0.198
Type of ECMO, No. (%)
   VA
   VV
 
 14 (82.4)
   3 (17.6)
 
45 (88.2)
  6 (11.8)
0.680
ECMO duration (hr, mean ± SD)    270.7 ± 238.2   78.4 ± 79.9 0.004
Less 24 hr alive after ECMO, No. (%)  1 (6%) 14 (27.5%) 0.092
iSOFA score (mean ± SD)  15.6 ± 2.0 15.0 ± 2.1 0.263
iSAPS II score (mean ± SD)    75.4 ± 16.8   84.8 ± 17.7 0.058
Laboratory findings (mean ± SD)
   iHematocrit (%)
   iPlatelets (× 10
3/mL)
   iPT/aPTT (sec)
   iBUN/Cr (mg/dL)
   pBUN/Cr (mg/dL)
   iTB/DB (mg/dL)
   pTB/DB (mg/dL)
 
 37.6 ± 7.3
192.2 ± 115
      14.5 ± 5.6/60.3 ± 42.8
26.0 ± 26.7/2.7 ± 5.1
62.8 ± 31.1/3.2 ± 2.8
    1.4 ± 1.6/0.9 ± 1.5
14.1 ± 14.3/9.9 ± 9.8
 
38.3 ± 5.4
  238.4 ± 105.7
    18.7 ± 20.9/54.0 ± 44.7
21.9 ± 11.7/1.4 ± 0.7
41.4 ± 29.3/2.2 ± 1.3
    1.0 ± 1.0/0.5 ± 0.7
    5.8 ± 6.6/3.6 ± 4.8
 
0.672
0.132
0.424/0.631
0.375/0.324
0.015/0.170
0.430/0.300
0.034/0.020
CRRT, No. (%)  13 (76.5) 27 (52.9) 0.154
SD, standard deviation; BMI, body mass index; AMI, acute myocardial infarction; ARDS, adult respiratory stress syndrome; ECMO, extracorporeal membrane oxygenation; CPR, 
cardiopulmonary resustitation; VA, venoarterial;  VV, venovenous; SOFA, Sepsis-related Organ Failure Assessment; SAPS, Simplified Acute Physiologic Score; i, initial; p, peak; 
BUN, blood urea nitrogen; Cr, creatinine; TB, total bilirubin; DB, direct bilirubin; CRRT, continuous renal replacement therapy.
Table 2. Comparison of the overall use of oxygenators, transfusions, thrombotic and 
hemorrhagic complications according to anticoagulants
Variables
Nafamostat  
mesilate  
(n = 17)
  Heparin  
  (n = 51) P value
No. of used oxygenators, No. (%)
   One
   Two
   Three
   Four or more
 
  6 (35.3)
  3 (17.7)
  3 (17.7)
  5 (29.3) 
 
   31 (60.8)
   10 (19.6)
   4 (7.8)
     6 (11.8)
0.178
Mean duration of oxygenator use 
   (hr/unit)
91.7 ± 57.3 41.6 ± 31.8 0.003
Blood products transfusion  
   (units/day)
   Packed RBC
   FFP
   Cryoprecipitate
   Platelet concentrates
 
1.6 ± 1.6
1.2 ± 1.0
1.3 ± 1.5
5.0 ± 4.6
 
7.5 ± 6.5
6.3 ± 5.7
2.5 ± 2.9
4.3 ± 4.3
 
< 0.001
< 0.001
0.035
0.559
Complications of bleeding or  
   thrombosis, No. (%)
   Cannular site bleeding
   Leg ischemia
   Gastrointestinal bleeding
   ICH
   Cerebral infarction
   Hemothorax
   Pulmonary hemorrhage
  4 (23.5)
0
  2 (11.8)
0
0
0
1 (5.9)
1 (5.9)
   31 (60.8)
   12 (23.5)
   2 (3.9)
   3 (5.9)
   3 (5.9)
1 (2)
     6 (11.8)
     7 (13.7)
0.011
RBC, red blood cell; FFP, fresh frozen plasma; ICH, intracerebral hemorrhage.
Table 3. Long-term survival and cause of death according to anticoagulants
Variables Nafamostat  
mesilate (n = 17)
  Heparin  
  (n = 51)
P value
Outcomes, No. (%)
   Died
   Wean-but-die (less 60 days)
   Survival (over 60 days)
     6 (35.5)
     4 (23.5)
     7 (41.2)
   30 (52.9)
   12 (23.5)
     9 (17.6)
0.048
Cause of death, No. (%)
   MOF
   Heart failure
   Hemorrhage
   Hypoxic brain damage
   ICH
   Pneumonia
10
  2 (20)
  4 (40)
  2 (20)
  1 (10)
0 (0)
  1 (10)
42
12 (29)
13 (31)
  8 (19)
  6 (14)
1 (2)
2 (5)
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an anticoagulant instead of heparin for extracorporeal oxygen-
ation, left ventricular assist devices, cardiac surgery, and hemo-
dialysis in patients at high risk of hemorrhage (5, 8, 9, 16). 
  The anticoagulant effect of nafamostat mesilate, like heparin, 
is dependent on the dosage; however, the ideal dosage of nafa-
mostat mesilate for ECMO has not yet been determined. Accord-
ing to 2 case studies that administered nafamostat mesilate in-
stead of heparin as an anticoagulant to treat pulmonary hemor-
rhage during ECMO use, Daimon et al. (10) and Kotani et al. (11) 
used a nafamostat mesilate infusion rate of 1.0 mg/kg/hr and 
1.0-1.7 mg/kg/hr, and ACT was maintained at 150 sec in a 49-yr-
old male patient and 190-200 sec in a 27-yr-old female patient, 
respectively. Nagaya et al. (8) successfully treated bleeding com-
plications in 12 neonates on ECMO by administering nafamo-
stat mesilate at 0.48 mg/kg/hr and heparin at 21.0 U/kg/hr, while 
ACT was maintained at 205.7 sec. In the present study, a nafa-
mostat mesilate infusion rate of 1.15-2.19 mg/kg/hr was need-
ed to maintain an ACT of 140-180 sec in 3 patients; however, in 
the other patients, the infusion rate of nafamostat mesilate was 
lower (0.64 mg/kg/hr), while maintaining an aPTT of 60-80 sec. 
The test results of ACT are affected by patient characteristics and 
technical factors (17-19). In this study, the use of aPTT monitor-
ing in the nafamostat mesilate group might allow more precise 
control of anticoagulation than ACT monitoring. Thrombotic 
complications were not found at the lower dosage. Two cases of 
amputation due to leg ischemia occurred in patients who were 
diagnosed with septic shock; however, these were related to the 
existing disease, disseminated intravascular coagulation, and 
not to the insertion of the cannula. A patient who was diagnosed 
with AMI and acute aortic dissection died after 24 hr due to left 
hemothorax. Pulmonary hemorrhagic complications occurred 
in another patient who was diagnosed with septic shock, and he 
was relieved by nafamostat mesilate; however, the patient died 
after 404 hr on ECMO because of a previously existing disease. 
The incidence of bleeding complications in the nafamostat me-
silate group was less than in the heparin group.
  Transfusion with packed RBCs is needed because hemoglo-
bin levels are decreased during ECMO due to thrombocytope-
nia, hemolysis, and hemodilution caused by continuous system-
ic heparinization (20). Formica et al. (21) reported that a trans-
fusion volume of 3.1 units/day was required. Bakhtiary et al. (22) 
transfused 16.3 units of packed RBCs over an average of 6.3 day 
during ECMO. Patients with post-cardiotomy and non-cardiot-
omy received transfusions of 23.3 and 17.3 units of packed RBCs 
over an average of 5.5 and 11.6 day on ECMO, respectively (23). 
In the present study, the incidence of bleeding complications in 
the nafamostat mesilate group was significantly less than in the 
heparin group because 1.6 units/day of packed RBCs were trans-
fused in the nafamostat mesilate group compared to 7.5 units/
day in the heparin group. Such a large transfusion volume was 
needed in the heparin group because bleeding complications 
occurred in 31 patients, and, in particular, the greatest transfusion 
volume was used in the 13 patients who died from bleeding.
  We had to change the circuit every 2-3 days due to failure of 
the oxygenator because we do not have access to long-term sup-
port ECMO oxygenators. The average time on ECMO oxygen-
ators in the nafamostat mesilate group was 91.7 hr, which was 
longer than in the heparin group (41.6 hr) because 14 patients 
(27.5%) in the heparin group died within 24 hr. This was similar 
to the report of Sung et al. (24), in which short-term support 
ECMO was replaced once by the use of an oxygenator for 2-3 
days. The duration of ECMO for the nafamostat mesilate group 
was also longer than for the heparin group because 47% of the 
nafamostat mesilate patients underwent ECMO due to septic 
shock or ARDS, and 73% of the heparin patients underwent 
ECMO due to AMI. Therefore, the different existing diseases had 
differing recovery periods, resulting in the varying durations of 
ECMO (20, 25-27). 
  The recent animal study of Schwertz et al. (28) reported that 
complement and neutrophils were suppressed by nafamostat 
mesilate before reperfusion; therefore, myocardial damage was 
decreased after reperfusion. The survival rate of the AMI patients 
who were treated with nafamostat mesilate was 50% (3 of 6 pa-
tients), which was higher than in the patients who were treated 
with heparin (11%, 4 of 37 patients). However, additional stud-
ies are needed because the small number of patients is not suf-
ficient to determine whether the survival rate is increased due 
to decreased myocardial damage by nafamostat mesilate. 
  Results obtained in this study have several limitations. First, 
our data describe a retrospective analysis of our experience with 
mixed indication for ECMO implantation. Therefore it is difficult 
to exclude that higher prevalence of AMI and elderly in the hep-
arin group influenced our results. Second, this study is limited 
in its ability to suggest the ideal dosage of nafamostat mesilate 
because it is a retrospective examination of a small number of 
patients who underwent ECMO for various diagnoses. However, 
in the present study, the incidence of bleeding complications 
and transfusions in patients on ECMO decreased when a lower 
dosage of nafamostat mesilate was needed maintain the aPTT 
than for the dosages used in previous studies to maintain the 
ACT. Higher amounts of peak total and direct bilirubin were ob-
served in the nafamostat mesilate patients than in the heparin 
patients; however, additional studies are needed to examine 
whether this was caused by the long-term administration of na-
famostat mesilate or existing diseases.
  In conclusion, nafamostat mesilate should be considered as 
an alternative anticoagulant to heparin to reduce bleeding com-
plications during ECMO. 
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Use of Nafamostat Mesilate as an Anticoagulant during Extracorporeal Membrane 
Oxygenation
Sang Jin Han, Hyoung Soo Kim, Gun Il Kim, Sung Mi Whang, Kyung Soon Hong, Won Ki Lee and Sun Hee Lee 
We investigated the effective dosage and efficacy of nafamostat mesilate for use with extracorporeal membrane oxygenator 
(ECMO) in patients with acute cardiac or respiratory failure. The daily volume of transfused packed red blood cells, fresh frozen 
plasma, and cryoprecipitate was lower in patients treated with nafamostat mesilate than with heparin. Also, the number of 
complications related to hemorrhage and thrombosis was lower than the heparin group. Nafamostat mesilate could be considered 
as an alternative anticoagulant to heparin during ECMO.